Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
| Autor: | Benjamin Georgiades, Jie Chen, Jennifer S McGregor, Matthew W. McCarthy, Pedro L Gonzalez, Urania Rappo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
education.field_of_study medicine.drug_class business.industry Antibiotics Population Dalbavancin Overweight Poster Abstract medicine.disease_cause Methicillin-resistant Staphylococcus aureus Surgery Single dose regimen Abstracts Infectious Diseases Oncology Internal medicine medicine Skin structure medicine.symptom business education Gram-Positive Cocci |
| Zdroj: | Open Forum Infectious Diseases |
| ISSN: | 2328-8957 |
| Popis: | Background Dalbavancin is a lipoglycopeptide with activity against Gram-positive pathogens responsible for ABSSSI, including methicillin-resistant Staphylococcus aureus (MRSA), and is FDA-approved as a single- or two-dose regimen. The objective of this study was to assess efficacy and safety of dalbavancin for the treatment of ABSSSI among overweight and obese patients. Methods This was a subanalysis of a previously published randomized, double-blind, phase 3 trial of 698 patients with ABSSSI, defined as major abscess, cellulitis, or traumatic wound/surgical site infection and an area of erythema ≥75 cm2. Patients were randomized 1:1 to receive dalbavancin 1500 mg intravenously (IV) as a single dose or as two doses: 1000 mg on Day 1 and 500 mg on Day 8. The primary outcome measure was clinical response at 48–72 hours, defined as ≥20% reduction in infection-associated erythema. Clinical success (resolution or improvement in all signs and symptoms; no further antibiotic treatment needed) was assessed at Days 14 and 28. Safety was assessed at every visit. Results There were 237 patients with normal weight (BMI |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|